Twist Bioscience
Twist Bioscience's revenue rose 20.3% to $377 million in fiscal 2025. Its operating margin was −36.2%, up from −70.6% a year earlier. Free cash flow was −$76 million. The diluted share count rose 3.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Twist Bioscience does
Twist Bioscience makes synthetic DNA. Its core technology "writes" DNA on a silicon chip, which lets it build more than a million short pieces of DNA on each chip. The company says this cuts the chemicals needed per gene compared with older plate-based methods. It combines the chips with its own software and an online ordering platform.
It sells synthetic genes, tools for next-generation sequencing (machines and methods that read DNA), sample preparation products, and products and services for drug discovery, such as antibody discovery. Its customers are researchers and companies in health care, chemicals and materials, food and agriculture, and academic research, in many countries. Nearly all of its revenue so far has come from its synthetic DNA products, and it says it needs to grow its synthetic biology and sequencing product groups and spread into other areas.
Twist says it competes in a crowded field and that losing a few large customers could hurt its revenue. Its fiscal year ends on September 30.
Its biggest risks, as it describes them
- It has lost money in every period so far and may never become profitable.
- Nearly all its revenue comes from synthetic DNA products, so it depends on their continued success.
- It could lose a few large customers, which would cut its revenue.
- It competes in a crowded industry, and rivals may develop technology that replaces its products.
- It may be unable to keep revenue growing or to manage that growth.
Income statement
Twist Bioscience lost money in fiscal 2025: a net loss of $78 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 478 | 505 | 336 | 276 | 232 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −416.1x | −2,934.7x | −43,431.8x | −7,614.9x | — |
| Current ratio | 8.7x | 6.6x | 5.8x | 4.9x | 3.6x |
| Quick ratio | 8.2x | 6.2x | 5.3x | 4.5x | 3.3x |
Cash flow
Projections
Project Twist Bioscience's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Twist Bioscience shares on the open market, and 10 insiders sold $126.1 million, $110.8 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 24, 2026 | Emily M. LeproustChief Executive Officer, Director | Sold plan | 5,203 | $177.38 | $922,899 | Form 4 |
| Sep 21, 2026 | Emily M. LeproustChief Executive Officer, Director | Sold | 1,687 | $165.49 | $279,182 | Form 4 |
| Sep 21, 2026 | Dennis ChoSee Remarks | Sold | 348 | $165.49 | $57,591 | Form 4 |
| Sep 21, 2026 | Paula GreenSVP of Human Resources | Sold | 294 | $165.49 | $48,654 | Form 4 |
| Sep 17, 2026 | Emily M. LeproustChief Executive Officer, Director | Sold plan | 356,546 | $157.99 | $56.3 million | Form 4 |
| Sep 8, 2026 | Emily M. LeproustChief Executive Officer, Director | Sold | 2,302 | $122.62 | $282,271 | Form 4 |
| Sep 8, 2026 | Paula GreenSVP of Human Resources | Sold | 907 | $122.62 | $111,216 | Form 4 |
| Sep 8, 2026 | Dennis ChoSee Remarks | Sold | 412 | $122.62 | $50,519 | Form 4 |
| Sep 8, 2026 | Robert F. WernerChief Accounting Officer | Sold | 238 | $122.62 | $29,184 | Form 4 |
| Aug 25, 2026 | Emily M. LeproustChief Executive Officer, Director | Sold plan | 41,570 | $151.98 | $6.3 million | Form 4 |
| Aug 24, 2026 | Robert F. WernerChief Accounting Officer | Sold | 854 | $140.77 | $120,218 | Form 4 |
| Aug 21, 2026 | Emily M. LeproustChief Executive Officer, Director | Sold | 6,639 | $139.07 | $923,286 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −49.0% | 5.6% | 0.2% |
| Altman Z'' | 1.03 | −2.56 | −2.72 |
| Accruals ratio | −7.2% | −20.8% | −4.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Twist Bioscience side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Twist Bioscience | FY25 | 20.3% | −36.2% | −20.1% | — | — | — | |
| Krystal Biotech | FY25 | 33.9% | 41.5% | 48.5% | 43.6% | −5.0x | 5 | Compare |
| Arrowhead Pharmaceuticals | FY26 | −45.6% | −156.9% | −63.0% | — | — | 2 | Compare |
| Tarsus Pharmaceuticals | FY25 | 146.7% | −15.7% | −4.9% | — | — | 4 | Compare |
| ADMA Biologics | FY25 | 19.6% | 37.5% | 5.5% | 39.5% | −0.1x | 5 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 11 | 25 | 54 | 90 | 132 | 204 | 245 | 313 | 377 |
| Revenue growth | — | 136.2% | 113.9% | 65.7% | 46.9% | 53.8% | 20.4% | 27.7% | 20.3% |
| Gross profit | −13 | −7 | 7 | 29 | 52 | 84 | 90 | 133 | 191 |
| Research and development | 19 | 20 | 36 | 43 | 69 | 120 | 107 | 91 | 80 |
| Operating income | −58 | −71 | −109 | −140 | −153 | −235 | −217 | −221 | −136 |
| Net income | −59 | −71 | −108 | −140 | −152 | −218 | −205 | −209 | −78 |
| Diluted EPS (US$) | −24.49 | −25.51 | −3.92 | −3.57 | −3.15 | −4.04 | −3.60 | −3.60 | −1.30 |
| Diluted shares (millions) | 2,422 | 0 | 28 | 39 | 48 | 54 | 57 | 58 | 60 |
| Cash flow | |||||||||
| Cash from operations | −51 | −66 | −88 | −142 | −112 | −124 | −142 | −64 | −48 |
| Capital expenditure | 7 | 4 | 15 | 10 | 27 | 102 | 28 | 5 | 28 |
| Free cash flow | −58 | −70 | −103 | −152 | −139 | −226 | −170 | −69 | −76 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 3 | 11 | 17 | 37 | 80 | 30 | 51 | 64 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 31 | 81 | 138 | 290 | 478 | 505 | 336 | 276 | 232 |
| Debt incl. finance leases | — | 10 | 8 | 4 | — | — | — | — | — |
| Total assets | — | 116 | 187 | 399 | 702 | 961 | 776 | 614 | 642 |
| Total liabilities | — | 27 | 35 | 63 | 121 | 172 | 153 | 142 | 169 |
| Shareholders' equity | −133 | −201 | 152 | 336 | 581 | 789 | 623 | 473 | 473 |
| Margins and ratios | |||||||||
| Gross margin | −123.1% | −26.6% | 12.8% | 31.9% | 39.1% | 41.4% | 36.6% | 42.6% | 50.7% |
| Operating margin | −543.2% | −277.5% | −200.2% | −155.5% | −115.4% | −115.3% | −88.6% | −70.6% | −36.2% |
| Net margin | −550.9% | −280.2% | −198.0% | −155.3% | −114.9% | −107.0% | −83.5% | −66.7% | −20.6% |
| Free cash flow margin | −537.7% | −274.7% | −188.8% | −168.8% | −105.3% | −111.1% | −69.5% | −22.1% | −20.1% |
| Rule of 40 (growth + FCF margin) | — | −138.6% | −74.9% | −103.2% | −58.4% | −57.3% | −49.0% | 5.6% | 0.2% |
| Return on capital | — | — | — | −307.8% | — | — | — | — | — |
| Return on equity | — | — | — | −57.3% | −33.2% | −31.8% | −29.0% | −38.1% | −16.4% |
| Return on assets | — | — | −71.1% | −47.8% | −27.6% | −26.2% | −23.6% | −30.0% | −12.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |